Pitfalls in hemoglobin A1c measurement: when results may be misleading

Impact of diabetes duration and hyperglycemia on the progression of diabetic kidney disease: Insights from the KNHANES 2019-2021

BACKGROUND

Diabetes is a significant risk factor for chronic kidney disease, and diabetic kidney disease (DKD) is prevalent among patients with diabetes. Previous studies have indicated that the duration of diabetes and poor glycemic control are associated with an increased risk of DKD, but data on how the duration and severity of hyperglycemia specifically relate to DKD progression are limited.

AIM

To investigate the relationship between diabetes duration and glycemic control, and DKD progression in South Korea.

METHODS

We included 2303 patients with diabetes using the 2019-2021 Korea National Health and Nutrition Examination Surveys data. DKD was defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min per 1.73 m², urinary albumin-to-creatinine ratio ≥ 30 mg/g, or both. Diabetes duration and severity were classified into six categories each.

RESULTS

DKD prevalence was 25.5%. The DKD risk significantly increased in diabetes lasting 10-15 years or hemoglobin A1C (HbA1c) ≥ 8% compared to patients with newly diagnosed diabetes or HbA1c < 6.5%. Albuminuria developed with shorter diabetes duration and lower HbA1c than eGFR decline. The adjusted odds ratios for DKD were 3.77 [95% confidence interval (95%CI): 2.60-5.45] and 4.91 (95%CI: 2.80-8.63) in patients with diabetes lasting ≥ 20 years and HbA1c ≥ 10%, respectively, compared to those with new-onset diabetes and HgA1c < 6.5%.

CONCLUSION

Patients with diabetes lasting > 10 years or HbA1c > 8% had a higher risk of DKD, emphasizing the importance of early monitoring and management is crucial to prevent DKD progression.

Relationship between stress hyperglycaemic ratio (SHR) and critical illness: a systematic review

Stress-induced hyperglycemia (SIH) is a physiological response to acute or chronic stress characterized by elevated blood glucose levels. It is prevalent in both patients with and without diabetes, particularly those with acute or critical illnesses. The development of SIH is characterized by complex interactions among catecholamines, cortisol, and inflammatory mediators such as cytokines, resulting in increased hepatic glucose production and insulin resistance. While mild to moderate SIH may provide a protective mechanism during stress, prolonged or excessive hyperglycemia can exacerbate inflammation and oxidative stress, contributing to adverse outcomes in conditions such as acute myocardial infarction, heart failure, and cerebrovascular diseases. The stress-hyperglycemia ratio (SHR), defined as the ratio of admission glucose to estimated mean glucose (derived from glycated hemoglobin [HbA1c]), has emerged as a valuable tool for quantifying stress hyperglycemia. Unlike absolute glucose levels, the SHR accounts for background hyperglycemia and provides a more accurate indicator of the relative glucose elevation associated with critical illness. Extensive research has demonstrated a U-shaped or J-shaped relationship of the SHR with disease outcomes, indicating that both low and high SHRs are associated with increased mortality and morbidity. The SHR has shown significant predictive value in cardiovascular diseases (e.g., acute coronary syndrome, heart failure), cerebrovascular diseases (e.g., acute ischemic stroke, intracerebral hemorrhage), and infectious diseases (e.g., sepsis, pneumonia). It also plays a role in other conditions, such as acute pancreatitis and certain cancers. The ease of calculating the SHR from widely available admission glucose and HbA1c tests makes it a practical and valuable prognostic marker in clinical settings. This review examines the relationship between the SHR and critical illnesses, highlighting its mechanisms and predictive value across various diseases.

Glycated albumin and fructosamine do not improve accuracy of glycaemic control assessment in patients with conditions reported to affect HbA1c reliability

AIMS

HbA1c testing in African populations may be limited due to high prevalence of hemoglobinopathies, anaemia, malaria and renal impairment. We aimed to assess the performance of glycated albumin (GA) and fructosamine in comparison to HbA1c for determining glycaemic control in Africans living with type 2 diabetes.

METHODS

We compared the relationship between fructosamine, GA, and HbA1c with mean continuous glucose monitoring (CGM) glucose and assessed the impact of sickle cell trait (SCT), anaemia and renal impairment on the relationship between each measure and CGM glucose.

RESULTS

The overall association of HbA1c, GA and fructosamine with CGM glucose was similar (r = 0.88 [95%CI: 0.84, 0.91], 0.84 [0.79, 0.88] and 0.84 [0.79, 0.88]), respectively. For detecting those with mean CGM glucose >8 mmol/L HbA1c had similar diagnostic accuracy to GA and fructosamine, even in those with conditions reported to affect HbA1c performance (n = 63). We found no evidence that SCT (n = 43/192) altered the relationship between HbA1c, fructosamine or GA with CGM glucose (p > 0.3 for all). However, individuals with anaemia showed an underestimation of CGM glucose by HbA1c and fructosamine compared to those without anaemia (p for interaction <0.005 for both). In contrast, GA with average CGM glucose between those with anaemia and those without were not significantly different.

CONCLUSIONS

Switching to fructosamine or GA is unlikely to improve the accuracy of laboratory glycaemic monitoring beyond that of HbA1c in a population with high prevalence of conditions reported to affect HbA1c reliability.

Opportunistic screening for diabetes among urban Aboriginal adults during emergency department attendance

BACKGROUND

Aboriginal people have a high risk of type 2 diabetes (T2DM). Routine opportunistic testing using glycated hemoglobin (HbA1c) for diabetes in the emergency department (ED) offers an opportunity to detect undiagnosed diabetes and evaluate glycaemia for pre-existing diabetes.

AIMS

To evaluate the prevalence of pre-existing diabetes and assess random blood glucose (RBG) and HbA1c as screening tools for undiagnosed diabetes in Aboriginal people attending the ED.

METHODS

Demographic and RBG data were extracted for all Aboriginal adults presenting to a Sydney hospital ED over 6 months. Practitioners requested blood tests as per routine care, and in the final 3 months, HbA1c was automatically added to routine venous sampling. The primary outcome was change in diabetes diagnosis with the addition of HbA1c.

RESULTS

Overall, 1640 adult Aboriginal patients presented to the ED over 6 months (4.1% of all presentations), including 734 unique individuals tested during routine care. The prevalence of pre-existing T2DM was 12.0% (n = 88). Among those without known diabetes, 1.4% (n = 9) had glucose readings ≥11.1 mmol/L and 14.3% (n = 90) had glucose readings 7.0-11.0 mmol/L. For those without known diabetes with HbA1c measurement, there were 2.7% (n = 8) with HbA1c ≥6.5% and 4% (n = 12) with HbA1c 6.0%-6.4%. There was no overlap between those who had an HbA1c ≥6.5% and RBG ≥11.1 mmol/L.

CONCLUSIONS

There was a high prevalence of pre-existing diabetes among Aboriginal adults attending the ED. New diabetes diagnosis in the ED based on RBG or HbA1c was not common. Confirmatory testing for diabetes should be recommended to the general practitioners of patients in whom elevated HbA1c or RBG are identified.

The relationship between hemoglobin glycation index and all-cause mortality in ill critically patients with heart failure: a retrospective study in MIMIC-IV database

BACKGROUND

Heart failure (HF) is a major cause of mortality in critically ill patients and often requires intensive care. The hemoglobin glycation index (HGI), defined as the difference between predicted glycated hemoglobin (HbA1c) and measured HbA1c, may provide additional prognostic insights beyond traditional glycemic metrics.

METHODS

We conducted a retrospective analysis of 8,098 adult patients with HF from the MIMIC-IV database (2008-2022). All were first-time ICU admissions with available hematologic and metabolic data. Patients were stratified into three groups (T1 ≤ - 1.26, - 1.26 < T2 < 1.74, T3 ≥ 1.74) based on HGI. Baseline characteristics were recorded within 24 h of ICU admission, including demographic data, disease severity scores, comorbidities, and medication use. Logistic regression and Cox proportional hazards models assessed the associations between HGI and in-hospital, 30-day, and 1-year all-cause mortality, adjusting for age, sex, race, comorbidities, laboratory results, and relevant treatments. Restricted cubic spline (RCS) analysis was performed to examine potential non-linear relationships. We used sensitivity analyses to increase the confidence in our primary outcome.

RESULTS

Patients in the lowest HGI group (T1) had significantly higher in-hospital, 30-day, and 1-year mortality than those in the other two groups. Specifically, T1 showed an 18.6% in-hospital mortality rate, compared with 12.3% and 9.7% in T2 and T3, respectively (p < 0.001). Fully adjusted models revealed that each 1-unit increase in HGI was associated with an approximate 12% reduction in in-hospital mortality risk (OR = 0.88; 95%CI: 0.83-0.93), and an 3% decreased risk of 1-year all-cause mortality (HR 0.97; 95%CI0.94~1.00). RCS analysis indicated a J-shaped relationship between HGI and mortality, underscoring the heightened risk associated with very low HGI. We conducted sensitivity analyses by separately excluding missing data, diagnosed sepsis, and diagnosed hepatic impairment, consistent with the primary analysis.

CONCLUSIONS

In critically ill HF patients, extremely low HGI levels correlate with poorer short- and long-term survival. These findings suggest that HGI could serve as an adjunct risk stratification tool, prompting closer monitoring and potential intervention in patients with markedly low HGI.

Hemoglobin S Promotes Glycemic Dysregulation in a Mouse Model of Human Sickle Cell Disease

Hemoglobin S (HbS) presents a challenge to identifying glycemic dysregulation, as changes in red blood cell turnover produce inaccurate hemoglobin A1c (HbA1c) and incongruencies between HbA1c and other glycemic control measures. Concerningly, the prevalence of diabetes in those with HbS is rising, and studies demonstrate that HbS increases the risk of diabetes-related complications. Though a link between the sickle cell variant and HbA1c is reported, the precise mechanisms by which HbS affects glycemic control are unknown. Here, we utilized the Townes mouse model of sickle cell disease (SCD) to analyze the effect of sickle cell trait (SCT) and SCD on glucose homeostasis. We found that chow-fed SCD mice had greater ad libitum and fasting blood glucose than SCT or littermate controls from 8 to 20 weeks of age, along with declining fasting serum insulin with aging, regardless of sex. This was not a result of overt alterations in peripheral glucose or insulin tolerance, gross morphological changes in pancreatic structure, or deposition of iron in pancreatic islets. Furthermore, compared with age- and sex-matched SCT and littermate control mice, we found decreased pancreatic insulin content in 20-week-old SCD male mice and significantly reduced pancreatic islet area and β cell mass in SCD males and females. These findings suggest that having 2 copies of the HbS gene promotes early hyperglycemia and the development of pancreatic β cell dysfunction, which may enhance the risk for diabetes in this cohort.

Platelets indices clinical implications in diabetes mellitus: A broader insight

Platelet indices (PIs) including high mean platelet volume (MPV), plateletcrit (PLC), and platelet distribution width (PLDW) are associated with poor glycemic control. In addition, they can indicate prothrombotic and procoagulation risk among patients with diabetes. PI measurement is cheap, quick and fits healthcare system needs in remote outreaching areas in low-income countries. However, a broader insight into their clinical implications in diabetes is lacking. To achieve a wider understanding, we reviewed PubMed/MEDLINE, Google Scholar and Cochrane Library for relevant articles investigating the role of PIs in diabetes mellitus. No limitation to the publication date was applied, which included all articles published up to August 17, 2024. The terms used were MPV, PLC, PLDW, platelet large cell ratio, glycated hemoglobin (HbA1c), PIs, platelet activity and diabetes mellitus. Out of the 790 articles retrieved, 187 full texts were reviewed, and 44 were included. PIs, when measurements are done promptly and within 2 h, could be short-term pointers to glycemic control in the life span of the platelets (2 wk). PIs are easy to perform, cheap and useful in remote outreaching areas with limited facilities where measurement of HbA1c is not available or cost-effective. However, PIs are not specific and are affected by demographic factors, such as pregnancy, renal failure, medications, hemoglobin and duration of diabetes. PIs could be implemented with daily blood glucose to inform doctors in low-income countries about their patients' glycemic control and cardiovascular risk. An important application might be when blood glucose control is needed quickly (before elective surgery).

Association between stress hyperglycemia ratio and acute kidney injury development in patients with sepsis: a retrospective study

Background

Stress hyperglycemia ratio (SHR), which adjusts blood glucose levels using glycated hemoglobin to eliminate the influence of chronic hyperglycemia, has been demonstrated to have superior predictive value than absolute hyperglycemia. However, its predictive value for sepsis-associated acute kidney injury (SA-AKI) remains unclear. This study aimed to investigate the relationship between the SHR and the risk of developing SA-AKI.

Methods

Data were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Restricted cubic splines (RCS) were employed to depict the relationship between SHR and the likelihood of SA-AKI, determining an optimal cut-off value. Based on this threshold, patients were categorized into two groups. Logistic regression was utilized to evaluate SHR's predictive value for SA-AKI, with adjustments for confounding variables. Propensity score matching (PSM) was applied to balance baseline characteristics. Subgroup and sensitivity analyses were conducted.

Results

A total of 2,249 patients were included. The RCS curve indicated a non-linear positive association between SHR and the likelihood of SA-AKI (P for non-linearity < 0.001), with an optimal cut-off at 1.55. Accordingly, patients were divided into SHR ≤ 1.55 and SHR > 1.55 subgroups, comprising 1,131 and 1,118 individuals, respectively. A higher incidence of SA-AKI was observed in the SHR > 1.55 group (38.64% vs. 27.23%, P < 0.001). This association persisted after baseline adjustment through PSM. Logistic regression analysis confirmed that SHR > 1.55 was linked to increased odds of SA-AKI in both unadjusted (OR: 1.68, P < 0.001) and adjusted models (OR: 1.73, P < 0.001), with SHR ≤ 1.55 serving as the reference. In subgroup analysis, all subgroups consistently demonstrated a significant association between SHR > 1.55 and elevated odds of SA-AKI (all OR > 1). Sensitivity analysis validated that SHR > 1.55 remained significantly correlated with SA-AKI occurrence in the survival subgroup (OR: 1.46, P < 0.001) and the non-CKD subgroup (OR: 1.69, P < 0.001).

Conclusion

The findings indicate a non-linear positive relationship between SHR and the likelihood of SA-AKI in patients with sepsis, suggesting that SHR could be a potential predictor for SA-AKI.

Comparative effectiveness of diabetes self-management education and support intervention strategies among adults with type 2 diabetes in Texas

Background

With approximately 1-in-10 Texas estimated to be living with Type 2 Diabetes Mellitus (T2DM), and the steadily rising healthcare costs associated with non-managed T2DM, efforts are needed to help patients manage their diabetes and avoid costly health consequences. While many diabetes self-management interventions and solutions exist to improve health among people living with T2DM, less is known about the relative effectiveness of these interventions based on their delivery format and when used in combination. The purpose of this study was to identify the effectiveness of three intervention modalities to reduce hemoglobin A1c (A1c) among Texans with T2DM living in rural and urban settings.

Methods

A three-arm randomized controlled trial (RCT) was conducted from November 2020 through March 2022. The three modalities included: (1) asynchronous virtual education and support program with one-on-one follow-up counseling [i.e., virtual Making Moves with Diabetes (vMMWD)]; (2) technology-based education and support (i.e., TBES); and (3) combined modality where participants sequentially received vMMWD and TBES (i.e., combined). Data were collected at baseline and again at 3- and 6-month follow-up. Using an intent-to-treat analysis, constrained longitudinal data analysis models were fitted to identify and compare changes in A1c over time.

Results

Findings demonstrate the positive effects of all three intervention modalities (i.e., vMMWD, TBES, and combined) to significantly reduce A1c among participants. Longitudinal analyses identified that initial reductions in A1c at 3-month follow-up were sustained at 6-month follow-up. Findings were consistent among rural- and urban-residing participants.

Conclusion

This RCT highlights the universal benefits of self-paced virtual diabetes self-management interventions to reduce A1c among Texans with unmanaged T2DM. Such low-cost interventions may be widely applicable for different settings and populations.

The Usefulness of the Glucose Management Indicator in Evaluating the Quality of Glycemic Control in Patients with Type 1 Diabetes Using Continuous Glucose Monitoring Sensors: A Cross-Sectional, Multicenter Study

The Glucose Management Indicator (GMI) is a biomarker of glycemic control which estimates hemoglobin A1c (HbA1c) based on the average glycemia recorded by continuous glucose monitoring sensors (CGMS). The GMI provides an immediate overview of the patient's glycemic control, but it might be biased by the patient's sensor wear adherence or by the sensor's reading errors. This study aims to evaluate the GMI's performance in the assessment of glycemic control and to identify the factors leading to erroneous estimates. In this study, 147 patients with type 1 diabetes, users of CGMS, were enrolled. Their GMI was extracted from the sensor's report and HbA1c measured at certified laboratories. The median GMI value overestimated the HbA1c by 0.1 percentage points (p = 0.007). The measurements had good reliability, demonstrated by a Cronbach's alpha index of 0.74, an inter-item correlation coefficient of 0.683 and an inter-item covariance between HbA1c and GMI of 0.813. The HbA1c and the difference between GMI and HbA1c were reversely associated (Spearman's r = -0.707; p < 0.001). The GMI is a reliable tool in evaluating glycemic control in patients with diabetes. It tends to underestimate the HbA1c in patients with high HbA1c values, while it tends to overestimate the HbA1c in patients with low HbA1c.

Enhanced glucose processing in gestational diabetes diagnosis: Effects on health equity and clinical outcomes

OBJECTIVES

Gestational diabetes is diagnosed using an oral glucose tolerance test (OGTT), which has limited accuracy, reproducibility and practicality. We assessed the effect of enhanced pre-analytical glucose processing upon glucose concentrations, gestational diabetes diagnosis, health equity and pregnancy outcomes, and if HbA1c was a suitable alternative.

METHODS

We recruited pregnant women with ≥1 risk factor to a prospective observational cohort study of pregnancy hyperglycaemia, endocrine causes, lipids, insulin and autoimmunity (OPHELIA), from nine UK centres. During a 75 g antenatal OGTT (National Institute of Health and Care Excellence criteria), standard glucose processing was compared to enhanced glucose processing (storage on ice, rapid centrifugation, aliquoting and freezing <2.5 h).

RESULTS

We recruited 1308 participants of mean (SD) age 31.5 years (5.0) and BMI 33.0 kg/m2 (6.8) of 82.5% white ethnicity, representative of the UK population. Enhanced glucose processing resulted in glucose levels ~0.6 mmol/L higher than standard glucose processing, increasing gestational diabetes diagnosis from 9% to 22%. Women with gestational diabetes on enhanced but not standard glucose processing (n = 165) were younger (31.9 vs. 33.2 years, p = 0.035), with a higher BMI (36.5 vs. 33.9 kg/m2; p = 0.003), different ethnic distribution (p = 0.025) and delivered more large-for-gestational age infants (37.0% vs. 22.3%; p = 0.006) compared to women with gestational diabetes on standard processing alone. HbA1c was not a suitable alternative predictor of gestational diabetes diagnosis (Area under receiver operator curve 0.74; 95% CI 0.68-0.79).

CONCLUSIONS

An OGTT with enhanced glucose processing would support more accurate, equitable diagnosis of gestational diabetes, but with increased diagnosis rates.

Parameters of glycemic variability in continuous glucose monitoring as predictors of diabetes: a prospective evaluation in a non-diabetic general population

Objectives

To prospectively examine the ability of some glycemic variability metrics from continuous glucose monitoring (CGM) to predict the development of diabetes in a non-diabetic population.

Methods

A total of 497 non-diabetic patients from the AEGIS study were included. Participants used a CGM system (iPro2®) over a six-day period. The following parameters were analyzed: standard deviation (SD), coefficient of variation (CV) and mean amplitude of glucose excursion (MAGE). Six-years follow-up was performed. ROC curves were constructed to determine the predictive value of glycemic variability metrics. Sensitivity and specificity were calculated.

Results

Of the 497 participants, 16 women (4.9 %) and 9 men (5.2 %) developed diabetes. Initial HbA1c and fasting glucose levels were significantly higher in the participants who ultimately developed diabetes. Glycemic variability metrics were also significantly higher in these subjects (SD: 18 vs. 13 mg/dL; CV: 17 vs. 14 %; MAGE: 36 vs. 27 mg/dL; p<0.001 in all cases). SD showed the highest AUC (0.81), with a sensitivity of 80 % and a specificity of 72 % for a cut-off of 14.9 mg/dL. AUCs were higher in men for all metrics.

Conclusions

The metrics obtained by MCG, especially SD, are effective predictors of progression to type 2 diabetes in a non-diabetic population. These findings suggest that glycemic variability is useful for the early identification of subjects at a higher risk of developing diabetes.

Parámetros de variabilidad glucémica de la monitorización continua de glucosa como predictores de diabetes: evaluación prospectiva en una población general sin diabetes

Objetivos

Evaluar prospectivamente la capacidad de distintas métricas de variabilidad glucémica obtenidas mediante monitorización continua de glucosa (MCG) para la predicción del desarrollo de diabetes en una población sin diabetes.

Métodos

Se incluyeron 497 participantes sin diabetes del estudio AEGIS. Los participantes utilizaron un sistema de MCG (iPro2®) durante seis días. Se evaluaron las siguientes métricas: desviación estándar (SD), coeficiente de variación (CV) y amplitud media de las excursiones glucémicas (MAGE). Los sujetos fueron seguidos durante una media de 6 años. Se utilizaron curvas ROC para determinar la capacidad predictiva de las métricas de variabilidad glucémica y se calcularon la sensibilidad y especificidad.

Resultados

De los 497 participantes, 16 mujeres (4,9 %) y 9 hombres (5,2 %) desarrollaron diabetes. Las concentraciones iniciales de HbA1c y glucosa en ayunas fueron significativamente más altos en aquellos que progresaron a diabetes. Las métricas de variabilidad glucémica también fueron significativamente mayores en estos individuos (SD: 18 vs. 13 mg/dL; CV: 17 % vs. 14 %; MAGE: 36 vs. 27 mg/dL; p<0,001 en todos los casos). La SD mostró la mayor AUC (0,81), con una sensibilidad del 80 % y una especificidad del 72 % para un punto de corte de 14,9 mg/dL. Las AUC fueron mayores en hombres para todas las métricas estudiadas.

Conclusiones

Las métricas obtenidas por MCG, especialmente la SD, son predictores efectivos de la progresión a diabetes tipo 2 en una población sin diabetes. Estos hallazgos sugieren la utilidad de la variabilidad glucémica en la identificación temprana de individuos en riesgo de desarrollar diabetes.

Fructosamine as an Indicator for Glycemic Control in the Veteran Community

OBJECTIVE

Glycemic monitoring via Hemoglobin A1(HbA1c) proves to be inaccurate when a patient is diagnosed with a hemoglobinopathy/erythrocyte disorder. Moreover, any acute changes of glycemic intake within 6 weeks of blood sampling have been noted to impart a greater effect on HbA1c than the remaining days of the supposed overall 3-to-4-month average of glycemic control. Fructosamine, an alternative to HbA1c, allows physicians to analyze glycemic control in the presence of an underlying hemoglobinopathy/erythrocyte disorder. Fructosamine analyzes glycemic control over a two-to-three week period, compared to a 3-to-4-month period with HbA1c. Studies indicate that fructosamine is significantly correlated with HbA1c in various population types. Given the increased likelihood of hemaglobinopathies/erythrocyte disorders in the veteran population accompanied by the the necessity for tighter glycemic evaluation, fructosamine offers an assay for physician when analyzing glycemic control in veterans. The aim of our study was to evaluate the correlation of HbA1c and fructosamine in the veteran community. We hypothesize that fructosamine is significantly correlated with HbA1c in the veteran community and therefore can be used as an alternative assay in the Veterans Affairs.

MATERIALS AND METHODS

Following institutional review board review and exemption, a retrospective chart review was conducted at the Northport Veterans Affairs between the dates of December 2007 and December 2018. Inclusion criteria consisted of veterans above the age of 18 years with a HbA1c and fructosamine assay drawn from the same blood sample. Exclusion criteria consisted of veterans with an underlying hemoglobinopathy, erythrocyte disorder, or serum protein altering pathology. Linear regression analysis was conducted between HbA1c and fructosamine values. Linear regression equation, correlation coefficient, and coefficient of variance were reported. A paired t-test was conducted between assay HbA1c and predicted HbA1c from the determined regression equation.

RESULTS

A total of 156 veterans were included in this study. A correlation coefficient and coefficient of variance of 0.75 and 0.56 were calculated from regression analysis (P < 0.05). A regression equation of the following was determined: HbA1c{%} = 0.0154*Fructosamine (mmol/L)+ 3.121. Paired t-test of assay HbA1c (M = 8.17, standard deviation = 1.64) and predicted HbA1c (M = 8.21, standard deviation = 1.53) returned without significance for difference of paired values.

CONCLUSIONS

Given that both correlation coefficient and coefficient of variance were considered significantly strong and the paired t-test indicated no significant difference between assay HbA1c and predicted HbA1c, fructosamine can be considered as an alternative assessment of glycemic control compared to HbA1c in the veteran community. We advise physicians at the Veterans Affairs to use fructosamine as an assessment of glycemic control when a veteran is diagnosed with an underlying hemoglobinopathy/erythrocyte disorder or requires stringent analysis of glycemic control. Yet, at this point of time, fructosamine does not have the necessary data to indicate complete replacement of HbA1c with fructosamine.

Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus

The investigation of biomarkers for metabolic diseases such as type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH) reveals their potential for advancing disease treatment and addressing their notable overlap. The connection between MASH, obesity, and T2DM highlights the need for an integrative management approach addressing mechanisms like insulin resistance and chronic inflammation. Obesity contributes significantly to the development of MASH through lipid dysregulation, insulin resistance, and chronic inflammation. Selective biomarker targeting offers a valuable strategy for detecting these comorbidities. Biomarkers such as CRP, IL-6, and TNF-α serve as indicators of inflammation, while HOMA-IR, fasting insulin, and HbA1c are essential for evaluating insulin resistance. Additionally, triglycerides, LDL, and HDL are crucial for comprehending lipid dysregulation. Despite the growing importance of digital biomarkers, challenges in research methodologies and sample variability persist, necessitating further studies to validate diagnostic tools and improve health interventions. Future opportunities include developing non-invasive biomarker panels, using multiomics, and using machine learning to enhance prognoses for diagnostic accuracy and therapeutic outcomes.

The Role of HbA1c in the Follow-Up and Control of Diabetes Mellitus

Introduction HbA1c is a biomarker that plays an essential role in the diagnosis and follow-up of diabetic patients. The sensitivity and specificity of the biomarker may be affected by common comorbidities seen in individuals with diabetes mellitus, such as kidney affection, cardiac affection, iron deficiency anemia, hemolytic anemia, hemoglobinopathies, and drug consumption. Aim To assess the role of HbA1c in the follow-up and control of Diabetes Mellitus across different patient populations and clinical scenarios. Methodology A quantitative research design to investigate the impact of residence location (inside or outside the Saudi Arabia). Through an electronic questionnaire in English and translated into Arabic, it was published online using Google Forms (Google, Mountain View, California) and was divided into three sections. Results The number of participating patients was 412 diabetic patients; their average age was from 51 to 60 years, and most of them were male. The study found a high level of awareness among diabetics about the HbA1c test, their knowledge of its importance, and their ability to perform the analysis regularly and periodically every year. However, there is a lack of practice, as most participants only performed follow-up every more than a few months, and the value of the last HbA1c test ranged between seven and ten. The percentage of diabetic patients whose cumulative blood sugar was more than ten and who did not take any action after learning of their high percentage (35.7%). Conclusion Diabetes is one of the most common health problems that continue to spread worldwide. HbA1c testing may continue to be implemented as an essential part of the diagnostic and prognostic tool, resulting in better patient care and successful clinical outcomes. Testing for glycosylated hemoglobin levels should be done every three months. Patients and doctors should be cautioned not to rely exclusively on two-hour post-prandial blood glucose results, particularly in the case of insulin-dependent diabetes.

Abnormally Low HbA1c Caused by Hemolytic Anemia, a Case Report and Literature Review

Hemoglobin A1c is a widely used diagnostic tool for monitoring glycemic control in diabetes management. However, its accuracy can be influenced by various factors. We present a case of a 17-year-old boy with abnormally low Hemoglobin A1c levels caused by warm autoantibody-induced hemolytic anemia. This case highlights the importance of considering conditions that may affect erythrocyte survival, and the potential interferences when interpreting Hemoglobin A1c results to ensure accurate diagnosis and effective management of diabetes.

Telehealth Occupation-Based Coaching for Rural Parents of Children With Type 1 Diabetes: A Randomized Controlled Trial

IMPORTANCE

Because of the complexity of their child's diabetes management, parents often assume all care duties and report needing additional assistance to resume family routines.

OBJECTIVE

To examine the preliminary efficacy of a telehealth occupation-based coaching intervention for rural parents of a child living with Type 1 diabetes (T1D) to improve child glycemic levels, family quality of life, and parental self-efficacy.

DESIGN

Double-blinded, two-arm, pilot randomized controlled trial.

SETTING

Telehealth video conferencing at home.

PARTICIPANTS

16 dyads of rural parents and children ages 2 to 12 yr diagnosed with T1D.

INTERVENTION

Occupation-based coaching delivered through telehealth sessions, once weekly for 12 wk, informed by community partners.

OUTCOMES AND MEASURES

Child measures: hemoglobin A1c and glucose time in range. Family measures: Parenting Sense of Competence, World Health Organization Quality of Life Brief Questionnaire, Goal Attainment Scale, Evidence of Independent Capacity Rating Scale (EICRS), and caregiver talk.

RESULTS

Families in the intervention group were more likely to achieve family-centered participation goals (p = .006) than those in the controlled group. Caregiver talk increased significantly over the 12-wk period (p = .034), and the average rating on the EICRS also improved significantly (p < .001). There were no statistically significant changes in glycemic levels or family quality of life.

CONCLUSIONS AND RELEVANCE

OBC may be more efficacious in helping families to improve health management routines after a child's diagnosis with T1D than usual endocrinology care alone. Most child health outcomes were in target range at the start of the study; therefore, it was not expected to see significant improvements. Plain-Language Summary: Occupational therapy is an untapped resource in the provision of care for children with Type 1 diabetes (T1D). Occupational therapy practitioners can also provide families with evidence-based support to address the self-management skills of children with this chronic condition. This clinical trial examined the preliminary efficacy of a new 12-wk telehealth occupational therapy intervention for rural families with a child living with T1D to improve caregiver diabetes management skills, family participation, and child health. Families who received occupational therapy services were more likely to improve their family participation in meaningful activities and diabetes self-efficacy; however, there were no differences in the child's health outcomes or the family's quality of life.

The Performance of Three Systems of Glycated Hemoglobin Measurements Among Patients With Sickle Cell Trait in Basrah, Iraq

Background Hemoglobin variants may cause mismanagement of diabetes resulting from false glycated hemoglobin (HbA1c) results. The aim of this study was to compare the results obtained from three different HbA1c assay systems among patients with sickle cell trait (SCT) at Faiha Specialized Diabetes, Endocrine, and Metabolism Center (FDEMC) in Basrah. Methods A cross-sectional observational study was done in FDEMC in Basrah on patients with established diagnoses of diabetes mellitus. All samples were analyzed at FDEMC laboratory by using three different systems: Roche Cobas Integra Gen.2 (COBAS INTEGRA® 400 plus analyzer immunoassay) (Roche Diagnostics, Indianapolis, IN), a turbidimetric inhibition immunoassay (TINIA), Bio-Rad Variant II Turbo (Bio-Rad, Hercules, CA) Ion exchange HPLC method, and Bio-Rad D-10 (A1c program) (Bio-Rad, Hercules, CA) Ion exchange HPLC method. Results We enrolled 139 persons with diabetes and SCT compared with 70 controls with diabetes and no SCT. A significant difference in the mean HbA1c levels between Roche Cobas Integra Gen.2 and Bio-Rad Variant II Turbo in comparison with Bio-Rad D-10 (A1c program) across all strata of HbA1c in SCT. The highest difference was -0.5% in the stratum of HbA1c 7 to 9% group in Roche Cobas Integra Gen.2, while it was +0.8% in the stratum of HbA1c less than 7% in the SCT group. For the control group, the highest difference was -1.3%, seen in the stratum of HbA1c, more than 9% in the Roche Cobas Integra Gen.2, while the highest difference in the Bio-Rad Variant II Turbo was +0.5% in the same stratum. In both groups, the results of HbA1c were mostly higher in the Bio-Rad Variant II Turbo and lower in Roche Cobas Integra Gen.2. Conclusion Roche Cobas Integra Gen.2 and Bio-Rad Variant II Turbo methods are not preferred to be used in HbA1c estimation in areas where SCT is prevalent. Diagnosing or follow-up of glycemic control in patients with SCT needs critical reappraisal because of the limitation of methods used to measure HbA1c in Basrah.

From Trials to Practice: Implementing a Clinical Intervention in Community Settings

INTRODUCTION/OBJECTIVES

Diabetes increases the risk of complications, especially for vulnerable populations. Our previous randomized clinical trial (RCT), TIME (Telehealth-supported, Integrated Community Health Workers (CHWs), Medication access, group visit Education), showed the efficacy of CHW-led diabetes care. This study aimed to gather data on transitioning TIME from clinical trials to practical implementation.

METHODS

We conducted a 12-month RCT at a nonprofit community clinic using the Consolidated Framework for Implementation Research (CFIR). Participants, Hispanic adults without insurance and with type 2 diabetes (N = 58; 29/arm), were randomized to TIME (intervention) or usual care (control). The intervention included monthly group visits and weekly CHW mHealth contact (6 months, Action Phase), followed by quarterly visits and bi-monthly mHealth contact (6 months, Maintenance Phase). The research team provided tele-mentoring to the clinic team throughout the intervention. Outcomes included implementation measures including acceptability, adoption, appropriateness, cost, feasibility, fidelity, satisfaction, and effectiveness.

KEY RESULTS

The program showed high levels of fidelity (direct observation), adoption (CHW-participant contact: 844 successes of 957 attempts [88.2%]), and feasibility (3.4% attrition). The intervention's net savings was $16,435 ($566/participant). At 6 months, intervention participants had greater HbA1c reductions (-0.85% vs 0.35% [δ = 1.2%]; P = .004; effectiveness) compared to the control. At month 12, more intervention participants improved HbA1c (-0.52% vs 0.25% [δ = 0.8%], P = .062) and preventive care adherence (P < .0001) compared to the control. Surveys revealed high appropriateness (mean = 4.8/5.0 and 5.95/6.0), satisfaction (mean = 4.6/5.0), and acceptability (mean = 4.9/5.0) among providers, CHWs, participants, and stakeholders.

CONCLUSIONS

TIME met key early implementation measures, including strong engagement at both clinic and participant levels, while demonstrating cost savings and significant clinical improvements. These results support the transition of TIME from efficacy trials to practical, community-based diabetes care. Larger studies are needed to further evaluate these findings.

Age and Red Blood Cell Parameters Mainly Explain the Differences Between HbA1c and Glycemic Management Indicator Among Patients With Type 1 Diabetes Using Intermittent Continuous Glucose Monitoring

BACKGROUND

Glycated hemoglobin (HbA1c) is the gold standard to assess glycemic control in patients with diabetes. Glucose management indicator (GMI), a metric generated by continuous glucose monitoring (CGM), has been proposed as an alternative to HbA1c, but the two values may differ, complicating clinical decision-making. This study aimed to identify the factors that may explain the discrepancy between them.

METHODS

Subjects were patients with type 1 diabetes, with one or more HbA1c measurements after starting the use of the Freestyle Libre 2 intermittent CGM, who shared their data with the center on the Libreview platform. The 14-day glucometric reports were retrieved, with the end date coinciding with the date of each HbA1c measurement, and those with sensor use ≥70% were selected. Clinical data prior to the start of CGM use, glucometric data from each report, and other simultaneous laboratory measurements with HbA1c were collected.

RESULTS

A total of 646 HbA1c values and their corresponding glucometric reports were obtained from 339 patients. The absolute difference between HbA1c and GMI was <0.3% in only 38.7% of cases. Univariate analysis showed that the HbA1c-GMI value was associated with age, diabetes duration, estimated glomerular filtration rate, mean corpuscular volume (MCV), red cell distribution width (RDW), and time with glucose between 180 and 250 mg/dL. In a multilevel model, only age and RDW, positively, and MCV, negatively, were correlated to HbA1c-GMI.

CONCLUSION

The difference between HbA1c and GMI is clinically relevant in a high percentage of cases. Age and easily accessible hematological parameters (MCV and RDW) can help to interpret these differences.

Glycated albumin in pregnancy correlates negatively with body mass index and contributes to the risk of gestational diabetes mellitus

Objectives

The aims of our study were to establish a reference interval for glycated albumin (GA) in gestational week 30, to investigate whether GA can replace or reduce the need for oral glucose tolerance test (OGTT) in pregnancy, and to reassess the usefulness of body mass-index (BMI), age and fasting glucose in detection of gestational diabetes (GDM).

Design

and methods: We measured GA in 486 healthy pregnant women. Reference interval was calculated using the central 95 % of the results. ROC curves were created to assess the ability of GA, fasting glucose and BMI separately to detect GDM, and logistic regression analysis was used to estimate risk of developing GDM given the level of the same markers. Finally, multiple logistic regression analysis based on GA, fasting glucose and BMI was used to find a strategy of predicting a patient's risk of GDM.

Results

The reference interval for GA at week 30 of gestation is 6.8-10.3 %. The analysis has a low AUC (0.53) with respect to detecting GDM. It increases slightly to 0.64 when corrected for BMI, as GA is inversely correlated to BMI. Combining GA with fasting glucose and BMI at gestational weeks 16-20 could raise the AUC to 0.80.

Conclusion

GA cannot be recommended to replace OGTT for the diagnosis of GDM. Nor can it be used to identify women at risk of developing GDM. GA combined with fasting glucose and BMI in early pregnancy could be a useful model to estimate risk of GDM.

Plasma Glycated CD59 and Gestational Diabetes Mellitus: A Systematic Review

AIMS

Gestational diabetes mellitus (GDM) is a common complication of pregnancy worldwide. The standard method for screening GDM is the 75 g oral glucose tolerance test (OGTT). However, the OGTT is difficult, time-consuming and requires fasting, making it an inconvenient test for GDM. Researchers have turned their attention to alternative biomarkers for GDM. This study aimed to systematically investigate the potential of plasma glycated CD59 (pGCD59) as a new biomarker for GDM and its associated adverse pregnancy outcomes.

METHODS

The systematic review was performed in the PubMed, ISI Web of Science, Scopus and Google Scholar databases from 1/1/2000 to 4/1/2024, and relevant studies were selected based on the inclusion and exclusion criteria. The quality of the studies was assessed using the Newcastle-Ottawa scale.

RESULTS

The study revealed that pGCD59 levels before 20 weeks and during the second trimester of pregnancy have the potential to predict the results of the OGTT and also forecast adverse pregnancy outcomes, such as postpartum glucose intolerance (PP GI), neonatal hypoglycaemia (NH) and having large for gestational age (LGA) infants. The predictive ability of pGCD59 was found to be affected by the GDM status, especially body mass index (BMI).

CONCLUSIONS

In conclusion, pGCD59 may be a promising indicator of glucose levels and could serve as a new biomarker for GDM. However, additional studies are needed to establish a reliable reference range and cut-off value for pGCD59.

Continuous Glucose Monitoring vs Fingerstick Monitoring for Hemoglobin A1c Control in Veterans

Background

Patients with diabetes have traditionally been required to use fingerstick testing to self-monitor their glucose levels. However, continuous glucose monitors (CGMs) collect glucose readings throughout the day and display daily trends, which allow clinicians to individualize treatment to achieve hemoglobin A1c (HbA1c) goals and simplify medication regimens. While studies have shown that CGMs improve HbA1c levels compared to fingerstick testing, this research has focused on type 1 diabetes and excluded veterans and patients on insulin therapy.

Methods

This retrospective chart review used a crossover, self-controlled design conducted at the Veterans Affairs Sioux Falls Health Care System. Veterans with an active CGM prescription were included. The primary endpoint compared the change in HbA1c before and after initiation of a CGM.

Results

The mean baseline HbA1c for the 150 veterans included in this study was 8.6%. The change in HbA1c before CGM use was 0.003 and change in HbA1c after CGM use was -0.971. The primary endpoint of difference in HbA1c associated with CGM use was -0.969 (P = .0001). The overall mean change in total daily doses of insulin was -22 units. Subgroup analysis of change in HbA1c after CGM use by prescriber type was -0.97 for endocrinology, -0.7 for pharmacy, and -1.23 for primary care practitioners. The overall average HbA1c post-CGM use was similar across all prescriber types at 7.64%.

Conclusions

This study found veterans with type 2 diabetes and on insulin therapy demonstrated a significant reduction in HbA1c with CGM use compared with their baseline fingerstick monitoring. Use of a CGM may be beneficial in patients who require a reduction in HbA1c by allowing more precise adjustments to medications to optimize therapy.

Establishment and application of autoverification system for HbA1c testing

Introduction

This study aimed to determine autoverification rules for routine glycated hemoglobin (HbA1c) analysis based on high-performance liquid chromatography (HPLC) principle. Laboratory information system (LIS) and Bio-Rad D-100 Advisor software (Bio-Rad, Hercules, USA) with graphics recognition function were carriers for the autoverification system.

Materials and methods

A total of 105,126 HbA1c results, including 98,249 HbA1c matching fast plasma glucose (FPG) results of real-world data from May 2019 to June 2020, were collected to determine autoverification rules including flags, delta checks, reporting limits, and logical rules. The validation database was composed of 48,045 HbA1c results and 41,083 matching FPG results. Autoverification passing rate and the reduction of turnaround time (TAT) were evaluated.

Results

Four autoverification systems (A, B, C, D) were established by two types of delta check rules, 28 flags, one reporting limits, and two kinds of logical rules. The autoverification passing rates were 80.6%, 78.8%, 83.7%, and 81.3%, and the average time saved in TAT were 117.5 min, 116.7 min, 121.1 min, and 121.7 min, respectively.

Conclusions

Autoverification system C was the optimal one. Application of distribution of FPG corresponding to HbA1c groups had better performance as logical rules. Established HbA1c autoverifcation system shortened the auditing report time and improved work efficiency.

Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure

Value-based diabetes care is a proactive approach to providing quality care to individuals with diabetes. This approach focuses on improving clinical outcomes rather than the volume of services provided. Implementation of value-based diabetes care requires an established set of standardized quality measures against which all stakeholders can assess and benchmark their performance. The National Committee for Quality Assurance recently added the Glucose Management Indicator to its Healthcare Effectiveness Data and Information Set. The Glucose Management Indicator can be used as a measure of glucose control. This article discusses the benefits of value-based care, the importance of diabetes quality measures, and how the rapidly increasing adoption of continuous glucose monitoring is impacting these measures while improving the lives of individuals with diabetes.

The Effects of Laparoscopic Sleeve Gastrectomy on Body Mass Index (BMI) and Glycated Hemoglobin (HbA1c) Levels

Background and significance Bariatric surgery is an effective surgical intervention for weight loss and metabolic improvement. Articles tackling obesity and bariatric surgery with its preoperative preferences and postoperative findings are needed. From that stance, we aim to accurately document the impact of bariatric surgery, particularly laparoscopic sleeve gastrectomy (LSG), on body mass index (BMI) and glycated hemoglobin (HbA1c) levels. Patients and methods We present a retrospective cohort study conducted on 111 LSG patients from a total of 1633 patients who underwent bariatric surgery from January 23, 2018, to December 31, 2019, at King Saud University Medical City in Riyadh, Saudi Arabia. Patients were divided into three groups: nondiabetics, prediabetics, and diabetics. For each group, demographic characteristics as well as preoperative and postoperative BMI and HbA1c values were collected. Results The mean patient age was 41.35±11.8 years, with 56.8% being female. Our analysis showed that BMI values for all three groups had a significant and nearly similar overall decrease in value postoperatively (mean difference: 14.43, p<0.001). HbA1c levels also significantly improved, with the largest reduction seen in the diabetic group (from 8.7±1.5 to 6.6±1.4, p<0.001), followed by the prediabetic group (from 5.9±0.2 to 5.4±0.3, p<0.001) and the nondiabetic group (from 5.4±0.1 to 5.2±0.3, p=0.003). Conclusion LSG leads to significant improvements in BMI and HbA1c levels. Postoperatively, diabetic patients showed the greatest reduction in HbA1c percentage, supporting LSG's role in enhancing metabolic health.

Interference in HbA1c measurement: a case of electropherogram shift due to hyperleukocytosis leading to the discovery of leukemic mantle cell lymphoma

HbA1c is a pivotal biomarker in diabetes management, reflecting long-term glycaemic control. HbA1c is often measured with capillary electrophoresis, which generally is a very precise technique, but there can be interference, especially in the case of haemoglobin diseases. Thus, in patients with underlying conditions, the accurate measurement of HbA1c can be challenging. We present a case of special interference in a 74-year-old female patient referred to a HbA1c test, in whom the measurement was thought to be significantly affected by hyperleukocytosis and led to an unexpected diagnosis of leukemic low-grade lymphoma. This case report highlights the underrecognized potential interference of leukocytosis in HbA1c measurement. It underscores the importance of clinical vigilance when interpreting HbA1c results in patients with underlying haematological conditions.

The Feasibility of the Diabetes Self-Management Coaching Program in Primary Care: A Mixed-Methods Randomized Controlled Feasibility Trial

BACKGROUND

Diabetes mellitus, a chronic metabolic disorder associated with elevated blood sugar levels, is a significant cause of morbidity, mortality, and disability globally. The rampant rise in the prevalence of diabetes presents a public health burden and a challenge to the primary care setting. Diabetes self-management coaching is an emergent, client-centered, solution-focused approach to enhance self-efficacy and self-care behavior, control glycemia, and prevent acute and chronic complications. Currently, there is no diabetes self-management support strategy in the primary care setting in Ethiopia. Therefore, this study assessed the feasibility, acceptability, and fidelity of implementing the Diabetes Self-Management Coaching Program in primary care in Ethiopia.

METHOD

A single-center, single-blinded, parallel group mixed-methods feasibility randomized control design was applied to assess the feasibility, acceptability, and fidelity of the Diabetes Self-Management Coaching Program in primary care. Adult patients with type 2 diabetes with HbA1c ≥ 7%, taking diabetic medication, and living in Gondar town were included in the study. A block randomization technique with a block size of four was used to allocate participants into the treatment and control groups. The treatment group attended a 12-week Diabetes Self-Management Coaching Program in addition to undergoing usual care, while the control group received the usual care for the same period. Data were collected at baseline, at the end of the intervention, and after the follow-up period. Descriptive statistics such as the frequency, mean, median, and standard deviations were computed. Based on the normality assessment, the baseline group difference was examined using the independent sample Student's t-test, the Mann-Whitney U test, and the chi-square test.

RESULT

This study's eligibility, recruitment, retention, and adherence rates were 23%, 70%, 90%, and 85%, respectively. Both the qualitative and quantitative findings show that the program was feasible to implement in primary care and acceptable to the participants. The fidelity assessment of the Diabetes Self-Management Coaching Program indicates an appropriate intervention implementation.

CONCLUSIONS

This study demonstrated remarkable recruitment, retention, and adherence rates. The Diabetes Self-Management Coaching Program was feasible, acceptable, and implementable in primary care in Ethiopia. As a result, we recommend that a large-scale multi-center cluster randomized controlled trial with an adequate sample can be designed to evaluate the effect of the DSM Coaching Program on clinical and behavioral outcomes.

Sustained metabolic dysregulation and the emergence of diabetes: associations between HbA1c and metabolic syndrome components in Tunisian diabetic and nondiabetic groups

INTRODUCTION

Metabolic Syndrome (MetS), diabetes, and other noncommunicable diseases (NCDs) have been a major focus of research in recent decades as the prevalence of these conditions continues to rapidly increase globally. However, the timing and patterns of development from metabolic risk factors to disease states are less well understood and are especially critical to understand in low- and middle-income countries (LMICs) and populations undergoing epidemiological transitions.

METHODS

Nationally representative sociodemographic, anthropometric, and point-of-care biomarker data from the 2016 Tunisian Health Examination Survey (n = 8170) were used to determine the prevalence of diabetes and MetS components in Tunisia and to investigate associations between glycated hemoglobin (HbA1c) and MetS components (blood pressure [BP], HDL cholesterol [HDL], triglycerides [TG], and waist circumference [WC]) in participants aged 15-97 years old. To better understand how sustained metabolic dysregulation and disease states impact these associations, diabetic and nondiabetic groups were analyzed separately.

RESULTS

The overall prevalence of diabetes based on measured HbA1c was 18.2%. The diabetic groups had a higher prevalence of each individual MetS component, and significantly higher (BP, TG, WC, and HbA1c) and lower (HDL) values than the nondiabetic groups. Yet, there were a higher number of significant associations between HbA1c and MetS components found in nondiabetic women and men when compared to diabetic women and men. HbA1c was positively associated with the cumulative number of MetS components, irrespective of diabetes status in men and women.

CONCLUSIONS

The prevalence of both diabetes and MetS components (particularly low HDL cholesterol and elevated TG) is high among the Tunisian population. More MetS components were associated with HbA1c in nondiabetic individuals, showing a strong connection between the development of MetS components and diabetes. However, once the diabetes disease state manifests, there is more variability in the relationships. These results show the potential for HbA1c to be an indicator of metabolic health below clinical disease cutoffs, which may allow insights into the physiological changes that precipitate the emergence of diabetes.

The association between glycated hemoglobin levels and long-term prognosis in patients with diabetes and triple-vessel coronary disease across different age groups: A cohort study

AIM

Our study aimed to investigate the correlation between glycated hemoglobin (HbA1c) and adverse prognostic events in patients with diabetes and triple-vessel coronary disease (TVD).

METHODS

This study ultimately included 2051 patients with TVD and diabetes. Patients were categorized into five groups based on their HbA1c levels: < 6.0 %, 6.0-6.4 %, 6.5-6.9 %, 7.0-7.9 %, and ≥ 8.0 %. The primary endpoint was all-cause death, and the secondary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE).

RESULTS

The median follow-up time was 5.88 years. During this period, a total of 323 (15.7 %) all-cause deaths and 537 (26.2 %) MACCEs were recorded. The relationship between HbA1c and the risk of endpoint events showed a J-shaped pattern, with the lowest risk observed between 6.0 % and 6.4 %. Further analysis revealed a significant interaction between HbA1c and age. In the subgroup with age < 70 years, as HbA1c increased, the risk of endpoint events gradually rose. While in the subgroup with age ≥70 years, there was an L-shaped relationship between HbA1c and endpoint events, with the highest risk observed in patients with HbA1c < 6.0 %.

CONCLUSION

Our study revealed variations in the relationship between HbA1c levels and endpoint events among patients with TVD and diabetes of different ages. In younger patients, elevated HbA1c levels were associated with a higher risk of death and MACCE, while in older patients, excessively low HbA1c levels (HbA1c < 6 %) were linked to a higher risk of death and MACCE.

Continuous glucose monitoring in pregnant women with pregestational type 2 diabetes: a narrative review

Background: Type 2 diabetes (T2DM) in pregnancy is associated with poor perinatal outcomes; however, there are limited data on outcomes of continuous glucose monitoring (CGM) use in this population. Objective: We reviewed the literature on studies reporting CGM outcomes in pregnant women with T2DM. We aimed to synthesise in a narrative review, the effects of CGM on glycaemic and perinatal outcomes as well as current research gaps. Results: Of 34 articles screened, three reported CGM outcomes in T2DM pregnancies compared to self-monitoring of blood glucose (SMBG). Other feasibility and mixed population studies were also reviewed. CGM in T2DM has good feasibility, acceptability, and improved glycaemic control beyond SMBG. There were limited data to draw conclusions on its effect on maternal and fetal outcomes. Conclusion: Further studies of perinatal outcomes in pregnant women with T2DM are required to determine the impact of improved glycaemia with CGM.

Eight Weeks of Intermittent Exercise in Hypoxia, with or without a Low-Carbohydrate Diet, Improves Bone Mass and Functional and Physiological Capacity in Older Adults with Type 2 Diabetes

In an increasingly aging and overweight population, osteoporosis and type 2 diabetes (T2DM) are major public health concerns. T2DM patients experience prejudicial effects on their bone health, affecting their physical capacity. Exercise in hypoxia (EH) and a low-carbohydrate diet (LCD) have been suggested for therapeutic benefits in T2DM, improving bone mineral content (BMC) and glycemic control. This study investigated the effects of EH combined with an LCD on body composition and functional and physiologic capacity in T2DM patients. Older T2DM patients (n = 42) were randomly assigned to the following groups: (1) control group: control diet + exercise in normoxia; (2) EH group: control diet + EH; (3) intervention group: LCD + EH. Cardiopulmonary tests (BRUCE protocol), body composition (DEXA), and functional capacity (6MWT, handgrip strength) were evaluated. Body mass index (kg/m2) and body fat (%) decreased in all groups (p < 0.001). BMC (kg) increased in all groups (p < 0.001) and was significantly higher in the EH and EH + LCD groups (p < 0.001). VO2peak improved in all groups (p < 0.001), but more so in the hypoxia groups (p = 0.019). Functional capacity was increased in all groups (p < 0.001), but more so in the EH group in 6MWT (p = 0.030). EH with and without an LCD is a therapeutic strategy for improving bone mass in T2DM, which is associated with cardiorespiratory and functional improvements.

Association Between Hemoglobin A1c and Development of Cardiovascular Disease in Canadian Men and Women Without Diabetes at Baseline: A Population-Based Study of 608 474 Adults

BACKGROUND

We examined the association between hemoglobin A1c (HbA1c) and the development of cardiovascular disease (CVD) in men and women, without diabetes or CVD at baseline.

METHODS AND RESULTS

This retrospective cohort study included adults aged 40 to <80 years in Alberta, Canada. Men and women were divided into categories based on a random HbA1c during a 3-year enrollment period. The primary outcome of CVD hospitalization and secondary outcome of combined CVD hospitalization/mortality were examined during a 5-year follow-up period until March 31, 2021. A total of 608 474 individuals (55.2% women) were included. Compared with HbA1c 5.0% to 5.4%, men with HbA1c of 5.5% to 5.9% had an increased risk of CVD hospitalization (adjusted hazard ratio [aHR], 1.12 [95% CI, 1.07-1.19]) whereas women did not (aHR, 1.01 [95% CI, 0.95-1.08]). Men and women with HbA1c of 6.0% to 6.4% had a 38% and 17% higher risk and men and women with HbA1c ≥6.5% had a 79% and 51% higher risk of CVD hospitalization, respectively. In addition, HbA1c of 6.0% to 6.4% and HbA1c ≥6.5% were associated with a higher risk (14% and 41%, respectively) of CVD hospitalization/death in men, but HbA1c ≥6.5% was associated with a 24% higher risk only among women.

CONCLUSIONS

In both men and women, HbA1c ≥6.0% was associated with an increased risk of CVD and mortality outcomes. The association between CVD and HbA1c levels of 5.5% to 5.9%, considered to be in the "normal" range, highlights the importance of optimizing cardiovascular risk profiles at all levels of glycemia, especially in men.

Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel

Despite the availability of various antihyperglycaemic therapies and comprehensive guidelines, glycaemic control in diabetes management has not improved significantly during the last decade in the real-world clinical setting. Treatment inertia arising from a complex interplay among patient-, clinician- and healthcare-system-related factors is the prime reason for this suboptimal glycaemic control. Also, the key factor leading to inadequate glycaemic levels remains limited communication between healthcare professionals (HCPs) and people with type 2 diabetes (PwT2D). Early insulin administration has several advantages including reduced glucotoxicity, high efficacy and preserved β-cell mass/function, leading to lowering the risk of diabetes complications. The current publication is based on consensus of experts from the South-Eastern European region and Israel who reviewed the existing evidence and guidelines for the treatment of PwT2D. Herein, the experts emphasised the timely use of insulin, preferably second-generation basal insulin (BI) analogues and intensification using basal-plus therapy, as the most-potent glucose-lowering treatment choice in the real-world clinical setting. Despite an increase in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the experts urged timely insulin initiation for inadequate glycaemic control in PwT2D. Furthermore, the combination of BI and GLP-1 RA addressing both fasting plasma glucose and post-prandial excursions as a free- or fixed-ratio combination was identified to reduce treatment complexity and burden. To minimise discontinuation and improve adherence, the experts reiterated quality, regular interactions and discussions between HCPs and PwT2D/carers for their involvement in the diabetes management decision-making process. Clinicians and HCPs should consider the opinions of the experts in accordance with the most recent recommendations for diabetes management.

The Role of Imatinib in Pediatric Type 1 Diabetes

We report the first case of imatinib use in an adolescent with diabetes and suggest that it impacts the natural course of disease. A 14-year-old male patient presented in diabetic ketoacidosis (DKA) and was diagnosed with presumed autoantibody-negative type 1 diabetes (T1D) as well as myeloid neoplasm with platelet-derived growth factor receptor beta (PDGFRB) rearrangement. After starting exogenous insulin and imatinib, he experienced a 1.7-point reduction in glycated hemoglobin (HbA1c) and a 71% reduction in insulin requirement with sustained partial diabetes remission. Our case suggests imatinib as a potential therapeutic agent for pediatric T1D.

Integrated modeling of labile and glycated hemoglobin with glucose for enhanced diabetes detection and short-term monitoring

Metabolic biomarkers, particularly glycated hemoglobin and fasting plasma glucose, are pivotal in the diagnosis and control of diabetes mellitus. Despite their importance, they exhibit limitations in assessing short-term glucose variations. In this study, we propose labile hemoglobin as an additional biomarker, providing insightful perspectives into these fluctuations. By utilizing datasets from 40,652 retrospective general participants and conducting glucose tolerance tests on 60 prospective pediatric subjects, we explored the relationship between plasma glucose and labile hemoglobin. A mathematical model was developed to encapsulate short-term glucose kinetics in the pediatric group. Applying dimensionality reduction techniques, we successfully identified participant subclusters, facilitating the differentiation between diabetic and non-diabetic individuals. Intriguingly, by integrating labile hemoglobin measurements with plasma glucose values, we were able to predict the likelihood of diabetes in pediatric subjects, underscoring the potential of labile hemoglobin as a significant glycemic biomarker for diabetes research.

Feasibility of diabetes self-management coaching program for individuals with type 2 diabetes in the Ethiopian primary care setting: a protocol for a feasibility mixed-methods parallel-group randomized controlled trial

BACKGROUND

Diabetes mellitus is the third most prevalent chronic metabolic disorder and a significant contributor to disability and impaired quality of life globally. Diabetes self-management coaching is an emerging empowerment strategy for individuals with type 2 diabetes, enabling them to achieve their health and wellness goals. The current study aims to determine the feasibility of a diabetes self-management coaching program and its preliminary effectiveness on the clinical and psychosocial outcomes in the Ethiopian primary healthcare context.

METHODS

The study will employ a mixed-method feasibility randomized controlled trial design. Forty individuals with type 2 diabetes will be randomly allocated to treatment and control groups using block randomization. The primary feasibility outcomes include acceptability, eligibility, recruitment, and participant retention rates, which will be computed using descriptive analysis. The secondary outcomes are self-efficacy, self-care activity, quality of life, and glycated hemoglobin A1c. For normally distributed continuous variables, the mean difference within and between the groups will be determined by paired sample Student t-test and independent sample Student t-test, respectively. Non-parametric tests such as the Mann-Whitney U test, the Wilcoxon signed rank test, and the Friedman analysis of variance test will determine the median difference for variables that violated the normality assumption. A repeated measure analysis of variance will be considered to estimate the variance between the baseline, post-intervention, and post-follow-up measurements. A sample of 10 volunteers in the treatment group will participate in the qualitative interview to explore their experience with the diabetes self-management coaching program and overall feasibility. The study will follow a qualitative content analysis approach to analyze the qualitative data. Qualitative and quantitative findings will be integrated using a joint display technique.

DISCUSSION

Evidence reveals diabetes self-management coaching programs effectively improve HbA1c, self-efficacy, self-care activity, and quality of life. This study will determine the feasibility of a future large-scale randomized controlled trial on diabetes self-management coaching. The study will also provide evidence on the preliminary outcomes and contribute to improving the diabetes self-management experience and quality of life of individuals with type 2 diabetes.

TRIAL REGISTRATION

The trial was registered online at ClinicalTrials.gov on 12/04/2022 and received a unique registration number, NCT05336019, and the URL of the registry is https://beta.

CLINICALTRIALS

gov/study/NCT05336019 .

Falsely low glycosylated haemoglobin levels probably secondary to hypersplenism in a patient with diabetes mellitus

A man in his 70s presented with a history of low glycated haemoglobin (HbA1c) values despite a diagnosis of type 2 diabetes. His blood glucose readings ranged between 8 and 15 mmol/L, but his HbA1c values were below 27 mmol/mol. Initial investigations demonstrated evidence of reduced red blood cell lifespan as a cause of misleadingly low HbA1c values. Further investigation revealed chronic liver disease and splenomegaly, with hypersplenism being the probable cause of increased red blood cell turnover. HbA1c estimation was no longer reliable, so ongoing diabetic care was guided by home capillary blood glucose monitoring. Healthcare providers and clinical laboratorians need to be aware of the possible clinical implications of very low HbA1c values in patients with type 2 diabetes.

Detection and Intervention: Use of Continuous Glucose Monitoring in the Early Stages of Type 2 Diabetes

The term "prediabetes" has been used to identify the state of abnormal glucose homeostasis (dysglycemia) that often leads to the development of clinical type 2 diabetes. However, this term does not describe the cellular changes that are already taking place in individuals with elevated glucose levels. This article describes our approach to detecting early dysglycemia using continuous glucose monitoring and explains how this approach can be integrated into clinical practice settings.

Diagnosis and management of pyruvate kinase deficiency: international expert guidelines

Pyruvate kinase (PK) deficiency is the most common cause of chronic congenital non-spherocytic haemolytic anaemia worldwide, with an estimated prevalence of one in 100 000 to one in 300 000 people. PK deficiency results in chronic haemolytic anaemia, with wide ranging and serious consequences affecting health, quality of life, and mortality. The goal of the International Guidelines for the Diagnosis and Management of Pyruvate Kinase Deficiency was to develop evidence-based guidelines for the clinical care of patients with PK deficiency. These clinical guidelines were developed by use of GRADE methodology and the AGREE II framework. Experts were invited after consideration of area of expertise, scholarly contributions in PK deficiency, and country of practice for global representation. The expert panel included 29 expert physicians (including adult and paediatric haematologists and other subspecialists), geneticists, laboratory specialists, nurses, a guidelines methodologist, patients with PK deficiency, and caregivers from ten countries. Five key topic areas were identified, the panel prioritised key questions, and a systematic literature search was done to generate evidence summaries that were used in the development of draft recommendations. The expert panel then met in person to finalise and vote on recommendations according to a structured consensus procedure. Agreement of greater than or equal to 67% among the expert panel was required for inclusion of a recommendation in the final guideline. The expert panel agreed on 31 total recommendations across five key topics: diagnosis and genetics, monitoring and management of chronic complications, standard management of anaemia, targeted and advanced therapies, and special populations. These new guidelines should facilitate best practices and evidence-based PK deficiency care into clinical practice.

Decreasing the Burden of Carbohydrate Counting and Meal Announcement with Automated Insulin Delivery, Meal Recognition, and Autocorrection Doses: A Case Study

The use of automated insulin delivery (AID) has led to a decrease in the burden of diabetes, allowing for better sleep, decreased anxiety about hypoglycemia, and automatic corrections doses, and meal recognition algorithms have provided "forgiveness" for imprecise carbohydrate (CHO) entries and missed or late meal boluses. We provide a case report and review of the current literature assessing the effect of AID on the burden of meal bolus. The case also demonstrates how sensor and pump data provide insight into insulin bolus behavior, and access to integrated cloud-based data has allowed for virtual patient visits. Glucose sensor metrics provides time in range and time below range, and the sensor-derived glucose management indicator provides an assessment of the long-term risk of complications when a laboratory glycated hemoglobin is not available.

Implementation and Evaluation of a mHealth-Based Community Health Worker Feedback Loop for Hispanics with and at Risk for Diabetes

BACKGROUND

Gaps in accessibility and communication hinder diabetes care in poor communities. Combining mobile health (mHealth) and community health workers (CHWs) into models to bridge these gaps has great potential but needs evaluation.

OBJECTIVE

To evaluate a mHealth-based, Participant-CHW-Clinician feedback loop in a real-world setting.

DESIGN

Quasi-experimental feasibility study with intervention and usual care (UC) groups.

PARTICIPANTS

A total of 134 participants (n = 67/group) who were all low-income, uninsured Hispanics with or at-risk for type 2 diabetes.

INTERVENTION

A 15-month study with a weekly to semimonthly mHealth Participant-CHW-Clinician feedback loop to identify participant issues and provide participants monthly diabetes education via YouTube.

MAIN MEASURES

We used pre-defined feasibility measures to evaluate our intervention: (a) implementation, the execution of feedback loops to identify and resolve participant issues, and (b) efficacy, intended effects of the program on clinical outcomes (baseline to 15-month HbA1c, systolic blood pressure (SBP), diastolic blood pressure (DBP), and weight changes) for each group and their subgroups (at-risk; with diabetes, including uncontrolled (HbA1c ≥ 7%)).

KEY RESULTS

CHWs identified 433 participant issues (mean = 6.5 ± 5.3) and resolved 91.9% of these. Most issues were related to supplies, 26.3% (n = 114); physical health, 23.1% (n = 100); and medication access, 20.8% (n = 90). Intervention participants significantly improved HbA1c (- 0.51%, p = 0.03); UC did not (- 0.10%, p = 0.76). UC DBP worsened (1.91 mmHg, p < 0.01). Subgroup analyses revealed HbA1c improvements for uncontrolled diabetes (intervention: - 1.59%, p < 0.01; controlled: - 0.72, p = 0.03). Several variables for UC at-risk participants worsened: HbA1c (0.25%, p < 0.01), SBP (4.05 mmHg, p < 0.01), DBP (3.21 mmHg, p = 0.01). There were no other significant changes for either group.

CONCLUSIONS

A novel mHealth-based, Participant-CHW-Clinician feedback loop was associated with improved HbA1c levels and identification and resolution of participant issues. UC individuals had several areas of clinical deterioration, particularly those at-risk for diabetes, which is concerning for progression to diabetes and disease-related complications.

CLINICAL TRIAL

NCT03394456, accessed at https://clinicaltrials.gov/ct2/show/NCT03394456.

To What Extent Is HbA1c Associated with Glycemic Variability in Patients with Type 1 Diabetes? A Retrospective, Noninterventional Study

BACKGROUND

Glycemic variability (GV) is a novel parameter used in evaluating the quality of diabetes management. Current guidelines recommend the use of GV indexes alongside the traditional parameter to evaluate glycemic control: hemoglobin A1c (HbA1c). This study aims to evaluate the extent to which HbA1c explains the GV phenomena in patients with Type 1 diabetes (T1DM).

METHODS

In 147 patients with T1DM, associations between HbA1c and several GV indexes were analyzed.

RESULTS

Patients with an HbA1c < 7% had a lower median standard deviation of glycemia (60 vs. 48; p < 0.001), a lower coefficient of variation (34.1 vs. 38.0; p < 0.001), and a significantly increased median time in range (78 vs. 58; p < 0.001). HbA1c was positively correlated with the coefficient of variation (r = 0.349; p < 0.001) and the standard deviation (r = 0.656; p < 0.001) but reversely correlated with a lower time in range (r = -0.637; p < 0.001).

CONCLUSIONS

HbA1c only partially explains the GV phenomena in patients with T1DM. The HbA1c value is associated more strongly with the time in range and standard deviation than with the coefficient of variation.